Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dose tailoring of dabigatran etexilate: obvious or excessive?

Expert opinion on drug safety - 1 Aug 2015

Douxfils Jonathan, Mullier François, Dogné Jean-Michel

Abstract excerpt

INTRODUCTION: Dabigatran etexilate is used for preventing blood clots and tends to replace older anticoagulants in many of their indications. However, the 'one dose fits all' policy is subject to criticism. Recent findings assert the anxiety of the scientific community concerning the pharmacokinetic properties of dabigatran etexilate, that is, an important interindividual variability including an important...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antithrombins
Share to Dose-Response Relationship, Drug
Share to Genetic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemorrhage

Share to Thrombosis

Source

Identifiers

PMID: 25994994
DOI: 10.1517/14740338.2015.1049995

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dose tailoring of dabigatran etexilate: obvious or excessive?PMID 25994994Read ↗

Pharmacogenetics of dabigatran etexilate interindividual variability.Semantic proximity Read ↗

Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?Semantic proximity Read ↗

Genetic determinants of dabigatran plasma levels and their relation to bleeding.Semantic proximity Read ↗

PHARMACOGENOMICS OF NOVEL ORAL ANTICOAGULANTS (NOACs): CURRENT INSIGHTS AND FUTURE DIRECTIONSSemantic proximity Read ↗

Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and PharmacogeneticsSemantic proximity Read ↗

Phenotype-directed clinically driven low-dose direct oral anticoagulant for atrial fibrillation.Semantic proximity Read ↗

Current challenges in personalizing warfarin therapy.Semantic proximity Read ↗

The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillationSemantic proximity Read ↗

Oral anticoagulation: a critique of recent advances and controversies.Semantic proximity Read ↗

The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillationSemantic proximity Read ↗

Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review.Semantic proximity Read ↗

Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.